<html>
  <head>
    <title></title>
    <!-- Licensed to: Broadridge Financial Solutions, Inc.
         Document created using Broadridge PROfile 22.7.2.5062
         Copyright 1995 - 2022 Broadridge -->
  </head>
<body style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;" bgcolor="#ffffff">
  <div>
    <hr style="border: none; border-bottom: 1px solid black; border-top: 4px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;" align="center">
    <div><br>
    </div>
    <div>
      <div style="text-align: center; color: #000000;">As filed with the Securities and Exchange Commission on August 24, 2022</div>
      <div style="text-align: right; color: #000000;">Registration No. 333-_________</div>
      <div><br>
      </div>
      <div>
        <hr style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;" align="center" noshade="noshade"></div>
      <div><br>
      </div>
      <div style="text-align: center; color: #000000; font-size: 14pt; font-weight: bold;">UNITED STATES</div>
      <div style="text-align: center; color: #000000; font-size: 14pt; font-weight: bold;">SECURITIES AND EXCHANGE COMMISSION</div>
      <div style="text-align: center; color: #000000; font-size: 12pt; font-weight: bold;">Washington, D.C. 20549</div>
      <div><br>
      </div>
      <div>
        <hr style="height: 2px; width: 25%; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;" align="center" noshade="noshade">
        <div> <br>
        </div>
      </div>
      <div style="text-align: center; color: #000000; font-size: 18pt; font-weight: bold;">FORM S-8</div>
      <div style="text-align: center; color: #000000; font-weight: bold;">REGISTRATION STATEMENT</div>
      <div style="text-align: center; color: #000000; font-weight: bold;">UNDER</div>
      <div style="text-align: center; color: #000000; font-weight: bold;">THE SECURITIES ACT OF 1933</div>
      <div><br>
      </div>
      <div style="text-align: center; color: #000000; font-size: 24pt; font-weight: bold;">PDS Biotechnology Corporation</div>
      <div style="text-align: center; color: #000000;">(Exact name of registrant as specified in its charter)</div>
      <div><br>
      </div>
      <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" id="z5b66514a7ad5434584870ca6eb34ada5" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 49.01%; vertical-align: top;">
              <div style="text-align: center; color: #000000; font-weight: bold;">Delaware</div>
            </td>
            <td style="width: 2%; vertical-align: top;">&#160;</td>
            <td style="width: 49%; vertical-align: top;">
              <div style="text-align: center; color: #000000; font-weight: bold;">26-4231384</div>
            </td>
          </tr>
          <tr>
            <td style="width: 49.01%; vertical-align: top;">
              <div style="text-align: center; color: #000000;">(State or other jurisdiction of incorporation or organization)</div>
            </td>
            <td style="width: 2%; vertical-align: top;">&#160;</td>
            <td style="width: 49%; vertical-align: top;">
              <div style="text-align: center; color: #000000;">(I.R.S. Employer Identification No.)</div>
            </td>
          </tr>

      </table>
      <div><br>
      </div>
      <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" id="zbabbb136d86f4a24b2e0b542434abb74" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 49.01%; vertical-align: top;">
              <div style="text-align: center; color: #000000; font-weight: bold;">25B Vreeland Road, Suite 300</div>
              <div style="text-align: center; color: #000000; font-weight: bold;">Florham Park, NJ</div>
            </td>
            <td style="width: 2%; vertical-align: top;">&#160;</td>
            <td style="width: 49%; vertical-align: top;">
              <div style="text-align: center; color: #000000; font-weight: bold;">07932</div>
            </td>
          </tr>
          <tr>
            <td style="width: 49.01%; vertical-align: top;">
              <div style="text-align: center; color: #000000;">(Address of Principal Executive Offices)</div>
            </td>
            <td style="width: 2%; vertical-align: top;">&#160;</td>
            <td style="width: 49%; vertical-align: top;">
              <div style="text-align: center; color: #000000;">(Zip Code)</div>
            </td>
          </tr>

      </table>
      <div><br>
      </div>
      <div style="text-align: center; color: #000000; font-weight: bold;">PDS Biotechnology Corporation 2019 Inducement Plan, as amended</div>
      <div style="text-align: center; color: #000000;">&#160;(Full title of the plans)</div>
      <div><br>
      </div>
      <div style="text-align: center; color: #000000; font-weight: bold;">Frank Bedu-Addo</div>
      <div style="text-align: center; color: #000000; font-weight: bold;">President and Chief Executive Officer</div>
      <div style="text-align: center; color: #000000; font-weight: bold;">PDS Biotechnology Corporation</div>
      <div style="text-align: center; color: #000000; font-weight: bold;">25B Vreeland Road, Suite 300</div>
      <div style="text-align: center; color: #000000; font-weight: bold;">Florham Park, NJ 07932</div>
      <div style="text-align: center; color: #000000; font-weight: bold;">(800) 208-3343</div>
      <div style="text-align: center; color: #000000;">(Name, address and telephone number, including area code, of agent for service)</div>
      <div style="text-align: center; color: #000000;"> <br>
      </div>
      <div>
        <hr style="height: 2px; width: 25%; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;" align="center" noshade="noshade"></div>
      <div><br>
      </div>
      <div style="color: #000000;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated
        filer&#8221; and &#8220;smaller reporting company&#8221; in Rule 12b-2 of the Exchange Act.</div>
      <div><br>
      </div>
      <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" id="z365bf708b0a444c8aebae45e6a2289d7" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 15%; vertical-align: middle;">&#160;</td>
            <td style="width: 35%; vertical-align: middle;">
              <div style="color: #000000;">Large Accelerated filer&#8195;<font style="font-family: 'Segoe UI Symbol', sans-serif;">&#9744;</font></div>
            </td>
            <td style="width: 50%; vertical-align: middle;">
              <div style="color: #000000;">Accelerated filer&#8195;<font style="font-family: 'Segoe UI Symbol', sans-serif;">&#9744;</font></div>
            </td>
          </tr>
          <tr>
            <td style="width: 15%; vertical-align: top;">&#160;</td>
            <td style="width: 35%; vertical-align: top;">
              <div style="color: #000000;">Non-accelerated filer&#8195;<font style="font-family: 'Segoe UI Symbol', sans-serif;">&#9746;</font></div>
            </td>
            <td style="width: 50%; vertical-align: middle;">
              <div style="color: #000000;">Smaller reporting company&#8195;<font style="font-family: 'Segoe UI Symbol', sans-serif;">&#9746;</font></div>
            </td>
          </tr>
          <tr>
            <td style="width: 15%; vertical-align: top;">&#160;</td>
            <td style="width: 35%; vertical-align: top;">&#160;</td>
            <td style="width: 50%; vertical-align: middle;">
              <div style="color: #000000;">Emerging growth company&#8195;<font style="font-family: 'Segoe UI Symbol', sans-serif;">&#9744;</font></div>
            </td>
          </tr>

      </table>
      <div><br>
      </div>
      <div style="color: #000000;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to
        Section 7(a)(2)(B) of the Securities Act.&#8195;<font style="font-family: 'Segoe UI Symbol', sans-serif;">&#9744;</font></div>
      <div style="color: #000000;"><font style="font-family: 'Segoe UI Symbol', sans-serif;"> <br>
        </font></div>
      <font style="font-family: 'Segoe UI Symbol', sans-serif;"> <br>
      </font>
      <div style="color: #000000;">
        <hr style="border: none; border-bottom: 4px solid black; border-top: 1px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;" align="center"><font style="font-family: 'Segoe UI Symbol', sans-serif;"> </font></div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
        <div style="page-break-after:always;" id="DSPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
      </div>
      <div><br>
      </div>
      <div>
        <div style="text-align: center; color: #000000; font-weight: bold;">Part II</div>
      </div>
      <div>
        <div><br>
        </div>
      </div>
      <div>
        <div style="text-align: center; color: #000000; font-weight: bold;">Information Required In The Registration Statement</div>
      </div>
      <div>
        <div><br>
        </div>
      </div>
      <div>
        <div style="text-align: justify; text-indent: 36pt;"><font style="color: #000000;">This Registration Statement relates to the registration of an additional 600,000 shares (the &#8220;</font><font style="font-weight: bold; font-style: italic; color: #000000;">Shares</font><font style="color: #000000;">&#8221;) of the Registrant&#8217;s Common Stock. The Shares are securities of the same class and relate to the same employee benefit plan, the PDS Biotechnology Corporation 2019 Inducement Plan, which
            was amended effective as of May 17, 2022 (in the form attached hereto as Exhibit 99.1) (the &#8220;</font><font style="font-weight: bold; font-style: italic; color: #000000;">Inducement Plan</font><font style="color: #000000;">&#8221;), as those registered
            pursuant to the Registrant&#8217;s registration statements on Form S-8, previously filed with the Securities and Exchange Commission on </font><a href="https://www.sec.gov/Archives/edgar/data/1472091/000114036119020567/forms8.htm">November 14, 2019
            (Registration No. 333-234693)</a> and <a href="https://www.sec.gov/Archives/edgar/data/1472091/000114036121037880/brhc10030771_s8.htm">November 15, 2021 (Registration No. 333-261072)</a><font style="color: #000000;">.</font></div>
        <div><br>
        </div>
        <div style="text-align: justify; text-indent: 36pt;"><font style="color: #000000;">In accordance with General Instruction E of Form S-8, the contents of the Registrant&#8217;s registration statements on Form S-8 filed with the Securities and Exchange
            Commission on </font><a href="https://www.sec.gov/Archives/edgar/data/1472091/000114036119020567/forms8.htm">November 14, 2019 (Registration No. 333-234693)</a> and <a href="https://www.sec.gov/Archives/edgar/data/1472091/000114036121037880/brhc10030771_s8.htm">November 15, 2021 (Registration No. 333-261072)</a><font style="color: #000000;"> are incorporated herein by reference (solely to the extent the
            contents of such registration statement relate to the Inducement Plan) and the information required by Part II is omitted, except as supplemented by the information set forth below.</font></div>
      </div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
        <div style="page-break-after:always;" id="DSPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
      </div>
      <div><br>
      </div>
      <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" id="z69fd8cc36db44eabba02a3652a5656b8" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 7.7%; vertical-align: top;">
              <div style="color: #000000; font-weight: bold;">Item 8.</div>
            </td>
            <td style="width: 92.3%; vertical-align: top;">
              <div style="color: #000000; font-weight: bold;">Exhibits.</div>
            </td>
          </tr>

      </table>
      <div><br>
      </div>
      <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" id="z54f588c9450a4b098c32cc9fd7abe71f" border="0" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 8%; vertical-align: middle;">
              <div style="text-align: center; color: #000000; font-weight: bold;">Exhibit No.</div>
            </td>
            <td style="width: 92%; vertical-align: middle;">
              <div style="text-align: center; color: #000000; font-weight: bold;">Description</div>
            </td>
          </tr>
          <tr>
            <td style="width: 8%; vertical-align: middle; background-color: rgb(204, 238, 255);">
              <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif;"><a href="https://www.sec.gov/Archives/edgar/data/1472091/000156761915001328/s000911x12_ex3-1.htm">4.1</a></div>
            </td>
            <td style="width: 92%; vertical-align: middle; background-color: rgb(204, 238, 255);">
              <div style="color: #000000;">Eighth Amended and Restated Certificate of Incorporation of the Registrant (incorporated by reference to Exhibit 3.1 to the Current Report on Form 8-K filed with the Commission on October 6, 2015).</div>
            </td>
          </tr>
          <tr>
            <td style="width: 8%; vertical-align: middle;">
              <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif;"><a href="https://www.sec.gov/Archives/edgar/data/1472091/000114036119005071/ex3_1.htm">4.2</a></div>
            </td>
            <td style="width: 92%; vertical-align: middle;">
              <div style="color: #000000;">Certificate of Amendment of the Eighth Amended and Restated Certificate of Incorporation of the Registrant (incorporated by reference to Exhibit 3.1 to the Current Report on Form 8-K filed with the Commission on
                March 18, 2019).</div>
            </td>
          </tr>
          <tr>
            <td style="width: 8%; vertical-align: middle; background-color: rgb(204, 238, 255);">
              <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif;"><a href="https://www.sec.gov/Archives/edgar/data/1472091/000114036119005071/ex3_2.htm">4.3</a></div>
            </td>
            <td style="width: 92%; vertical-align: middle; background-color: rgb(204, 238, 255);">
              <div style="color: #000000;">Certificate of Amendment of the Eighth Amended and Restated Certificate of Incorporation of the Registrant (incorporated by reference to Exhibit 3.2 to the Current Report on Form 8-K filed with the Commission on
                March 18, 2019).</div>
            </td>
          </tr>
          <tr>
            <td style="width: 8%; vertical-align: middle;">
              <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif;"><a href="https://www.sec.gov/Archives/edgar/data/1472091/000114036122009505/brhc10035198_ex3-1.htm">4.4</a></div>
            </td>
            <td style="width: 92%; vertical-align: middle;">
              <div style="color: #000000;">Third Amended and Restated Bylaws of the Registrant (incorporated by reference to Exhibit 3.1 to the Current Report on Form 8-K filed with the Commission on March 15, 2022).</div>
            </td>
          </tr>
          <tr>
            <td style="width: 8%; vertical-align: middle; background-color: rgb(204, 238, 255);">
              <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif;"><a href="https://www.sec.gov/Archives/edgar/data/1472091/000156761915001209/s000911x5_ex4-1.htm">4.5</a></div>
            </td>
            <td style="width: 92%; vertical-align: middle; background-color: rgb(204, 238, 255);">
              <div style="color: #000000;">Form of Certificate of Common Stock (incorporated by reference to Exhibit 4.1 to the Registrant&#8217;s Pre-Effective Amendment No. 1 to the Registration Statement on Form S-1 (File No. 333- 206416) filed with the
                Commission on September 21, 2015).</div>
            </td>
          </tr>
          <tr>
            <td style="width: 8%; vertical-align: middle;">
              <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif;"><a href="ny20005031x3_ex5-1.htm">5.1*</a></div>
            </td>
            <td style="width: 92%; vertical-align: middle;">
              <div style="color: #000000;">Opinion of DLA Piper LLP (US).</div>
            </td>
          </tr>
          <tr>
            <td style="width: 8%; vertical-align: middle; background-color: rgb(204, 238, 255);">
              <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif;"><a href="ny20005031x3_ex23-1.htm">23.1*</a></div>
            </td>
            <td style="width: 92%; vertical-align: middle; background-color: rgb(204, 238, 255);">
              <div style="color: #000000;">Consent of KPMG LLP.</div>
            </td>
          </tr>
          <tr>
            <td style="width: 8%; vertical-align: middle;">
              <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif;"><a href="ny20005031x3_ex5-1.htm">23.2*</a></div>
            </td>
            <td style="width: 92%; vertical-align: middle;">
              <div style="color: #000000;">Consent of DLA Piper LLP (US) (included in Exhibit 5.1).</div>
            </td>
          </tr>
          <tr>
            <td style="width: 8%; vertical-align: middle; background-color: rgb(204, 238, 255);">
              <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif;"><a href="#POWEROFATTORNEY">24</a></div>
            </td>
            <td style="width: 92%; vertical-align: middle; background-color: rgb(204, 238, 255);">
              <div style="color: #000000;">Power of Attorney (contained on the signature page hereto).</div>
            </td>
          </tr>
          <tr>
            <td style="width: 8%; vertical-align: middle;">
              <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif;"><a href="https://www.sec.gov/Archives/edgar/data/1472091/000114036122019709/brhc10037859_ex10-1.htm">99.1</a></div>
            </td>
            <td style="width: 92%; vertical-align: middle;">
              <div style="color: #000000;">PDS Biotechnology Corporation 2019 Inducement Plan, as amended (incorporated by reference to Exhibit 10.1 to the Current Report on Form 8-K filed with the Commission on May 18, 2022).</div>
            </td>
          </tr>
          <tr>
            <td style="width: 8%; vertical-align: middle;">
              <div style="text-align: center;"><a href="ny20005031x3_ex107.htm">107*</a></div>
            </td>
            <td style="width: 92%; vertical-align: middle;">
              <div style="color: #000000;">Filing Fee Table</div>
            </td>
          </tr>
          <tr>
            <td style="width: 8%; vertical-align: middle;">
              <div style="text-align: center;">*</div>
            </td>
            <td style="width: 92%; vertical-align: middle;">
              <div style="color: #000000;">Filed herewith</div>
            </td>
          </tr>

      </table>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
        <div style="page-break-after:always;" id="DSPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
      </div>
      <div><br>
      </div>
      <div style="text-align: center; color: #000000; font-weight: bold;">SIGNATURE</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt; color: #000000;">Pursuant to the requirements of the Securities Act of 1933, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on
        Form S-8 and has duly caused this Registration Statement with respect to the PDS Biotechnology Corporation 2019 Inducement Plan, as amended, to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Florham Park,
        State of New Jersey, on August 24, 2022.</div>
      <div><br>
      </div>
      <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" id="zc55e4dbf95884389989727cecb4ca531" border="0" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 49.59%; vertical-align: middle;">&#160;</td>
            <td colspan="2" style="vertical-align: middle;">
              <div style="color: #000000; font-weight: bold;">PDS Biotechnology Corporation</div>
            </td>
          </tr>
          <tr>
            <td style="width: 49.59%; vertical-align: middle;">&#160;</td>
            <td style="width: 6%; vertical-align: middle;">&#160;</td>
            <td style="width: 44%; vertical-align: middle;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 49.59%; vertical-align: middle;">&#160;</td>
            <td style="width: 6%; vertical-align: middle;">
              <div style="color: #000000;">By:</div>
            </td>
            <td style="width: 44%; vertical-align: middle; border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="color: #000000;">/s/ Frank Bedu-Addo</div>
            </td>
          </tr>
          <tr>
            <td style="width: 49.59%; vertical-align: middle;">&#160;</td>
            <td style="width: 6%; vertical-align: middle;">
              <div style="color: #000000;">Name:</div>
            </td>
            <td style="width: 44%; vertical-align: middle;">
              <div style="color: #000000;">Frank Bedu-Addo</div>
            </td>
          </tr>
          <tr>
            <td style="width: 49.59%; vertical-align: middle;">&#160;</td>
            <td style="width: 6%; vertical-align: middle;">
              <div style="color: #000000;">Title:</div>
            </td>
            <td style="width: 44%; vertical-align: middle;">
              <div style="color: #000000;">President and Chief Executive Officer</div>
            </td>
          </tr>

      </table>
      <div style="text-align: center;"><br>
      </div>
      <div style="text-align: center;"><br>
      </div>
      <div style="text-align: center; color: #000000; font-weight: bold;"><a name="POWEROFATTORNEY"><!--Anchor--></a>POWER OF ATTORNEY</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt; color: #000000;">The officers and directors of PDS Biotechnology Corporation whose signatures appear below hereby constitute and appoint Frank Bedu-Addo and Matthew Hill, and each of them, their
        true and lawful attorneys and agents, with full power of substitution, each with power to act alone, to sign and execute on behalf of the undersigned this Registration Statement on Form S-8 with respect to the PDS Biotechnology Corporation 2019
        Inducement Plan, as amended, and any amendment or amendments thereto, and each of the undersigned does hereby ratify and confirm all that each attorney and agent, or his or her substitutes, shall do or cause to be done by virtue hereof.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt; color: #000000;">Pursuant to the requirements of the Securities Act of 1933, this Registration Statement has been signed by the following persons in the capacities and on the date indicated.</div>
      <div><br>
      </div>
      <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" id="z5b4128aa86b5409cacf16cc896a90471" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 28%; vertical-align: middle;">
              <div style="text-align: center; color: #000000; font-weight: bold;">Signature</div>
            </td>
            <td style="width: 2%; vertical-align: middle;">&#160;</td>
            <td style="width: 40%; vertical-align: middle;">
              <div style="text-align: center; color: #000000; font-weight: bold;">Title</div>
            </td>
            <td style="width: 2.36%; vertical-align: middle;">&#160;</td>
            <td style="width: 27.64%; vertical-align: middle;">
              <div style="text-align: center; color: #000000; font-weight: bold;">Date</div>
            </td>
          </tr>
          <tr>
            <td style="width: 28%; vertical-align: middle;">&#160;</td>
            <td style="width: 2%; vertical-align: middle;">&#160;</td>
            <td style="width: 40%; vertical-align: middle;">&#160;</td>
            <td style="width: 2.36%; vertical-align: middle;">&#160;</td>
            <td style="width: 27.64%; vertical-align: middle;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 28%; vertical-align: middle; border-bottom: #000000 2px solid;">
              <div style="color: #000000;">/s/ Frank Bedu-Addo</div>
            </td>
            <td style="width: 2%; vertical-align: middle;">&#160;</td>
            <td style="width: 40%; vertical-align: middle;">
              <div style="text-align: center; color: #000000;">President, Chief Executive Officer and Director</div>
            </td>
            <td style="width: 2.36%; vertical-align: middle;">&#160;</td>
            <td style="width: 27.64%; vertical-align: middle;">
              <div style="text-align: center; color: #000000;">August 24, 2022</div>
            </td>
          </tr>
          <tr>
            <td style="width: 28%; vertical-align: middle; border-top: #000000 2px solid;">
              <div style="color: #000000;">Frank Bedu-Addo</div>
            </td>
            <td style="width: 2%; vertical-align: middle;">&#160;</td>
            <td style="width: 40%; vertical-align: middle;">
              <div style="text-align: center; color: #000000;">(Principal Executive Officer)</div>
            </td>
            <td style="width: 2.36%; vertical-align: middle;">&#160;</td>
            <td style="width: 27.64%; vertical-align: middle;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 28%; vertical-align: middle;">&#160;</td>
            <td style="width: 2%; vertical-align: middle;">&#160;</td>
            <td style="width: 40%; vertical-align: middle;">&#160;</td>
            <td style="width: 2.36%; vertical-align: middle;">&#160;</td>
            <td style="width: 27.64%; vertical-align: middle;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 28%; vertical-align: middle; border-bottom: #000000 2px solid;">
              <div style="color: #000000;">/s/ Matthew Hill</div>
            </td>
            <td style="width: 2%; vertical-align: middle;">&#160;</td>
            <td style="width: 40%; vertical-align: middle;">
              <div style="text-align: center; color: #000000;">Chief Financial Officer</div>
            </td>
            <td style="width: 2.36%; vertical-align: middle;">&#160;</td>
            <td style="width: 27.64%; vertical-align: middle;">
              <div style="text-align: center; color: #000000;">August 24, 2022</div>
            </td>
          </tr>
          <tr>
            <td style="width: 28%; vertical-align: middle; border-top: #000000 2px solid;">
              <div style="color: #000000;">Matthew Hill</div>
            </td>
            <td style="width: 2%; vertical-align: middle;">&#160;</td>
            <td style="width: 40%; vertical-align: middle;">
              <div style="text-align: center; color: #000000;">(Principal Financial and Accounting Officer)</div>
            </td>
            <td style="width: 2.36%; vertical-align: middle;">&#160;</td>
            <td style="width: 27.64%; vertical-align: middle;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 28%; vertical-align: middle;">&#160;</td>
            <td style="width: 2%; vertical-align: middle;">&#160;</td>
            <td style="width: 40%; vertical-align: middle;">&#160;</td>
            <td style="width: 2.36%; vertical-align: middle;">&#160;</td>
            <td style="width: 27.64%; vertical-align: middle;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 28%; vertical-align: middle; border-bottom: #000000 2px solid;">
              <div style="color: #000000;">/s/ Stephen Glover</div>
            </td>
            <td style="width: 2%; vertical-align: middle;">&#160;</td>
            <td style="width: 40%; vertical-align: middle;">
              <div style="text-align: center; color: #000000;">Director</div>
            </td>
            <td style="width: 2.36%; vertical-align: middle;">&#160;</td>
            <td style="width: 27.64%; vertical-align: middle;">
              <div style="text-align: center; color: #000000;">August 24, 2022</div>
            </td>
          </tr>
          <tr>
            <td style="width: 28%; vertical-align: middle; border-top: #000000 2px solid;">
              <div style="color: #000000;">Stephen Glover</div>
            </td>
            <td style="width: 2%; vertical-align: middle;">&#160;</td>
            <td style="width: 40%; vertical-align: middle;">&#160;</td>
            <td style="width: 2.36%; vertical-align: middle;">&#160;</td>
            <td style="width: 27.64%; vertical-align: middle;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 28%; vertical-align: middle;">&#160;</td>
            <td style="width: 2%; vertical-align: middle;">&#160;</td>
            <td style="width: 40%; vertical-align: middle;">&#160;</td>
            <td style="width: 2.36%; vertical-align: middle;">&#160;</td>
            <td style="width: 27.64%; vertical-align: middle;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 28%; vertical-align: middle; border-bottom: #000000 2px solid;">
              <div style="color: #000000;">/s/ Kamil Ali-Jackson</div>
            </td>
            <td style="width: 2%; vertical-align: middle;">&#160;</td>
            <td style="width: 40%; vertical-align: middle;">
              <div style="text-align: center; color: #000000;">Director</div>
            </td>
            <td style="width: 2.36%; vertical-align: middle;">&#160;</td>
            <td style="width: 27.64%; vertical-align: middle;">
              <div style="text-align: center; color: #000000;">August 24, 2022</div>
            </td>
          </tr>
          <tr>
            <td style="width: 28%; vertical-align: middle; border-top: #000000 2px solid;">
              <div style="color: #000000;">Kamil Ali-Jackson</div>
            </td>
            <td style="width: 2%; vertical-align: middle;">&#160;</td>
            <td style="width: 40%; vertical-align: middle;">&#160;</td>
            <td style="width: 2.36%; vertical-align: middle;">&#160;</td>
            <td style="width: 27.64%; vertical-align: middle;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 28%; vertical-align: middle;">&#160;</td>
            <td style="width: 2%; vertical-align: middle;">&#160;</td>
            <td style="width: 40%; vertical-align: middle;">&#160;</td>
            <td style="width: 2.36%; vertical-align: middle;">&#160;</td>
            <td style="width: 27.64%; vertical-align: middle;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 28%; vertical-align: middle; border-bottom: #000000 2px solid;">
              <div style="color: #000000;">/s/ Otis W. Brawley</div>
            </td>
            <td style="width: 2%; vertical-align: middle;">&#160;</td>
            <td style="width: 40%; vertical-align: middle;">
              <div style="text-align: center; color: #000000;">Director</div>
            </td>
            <td style="width: 2.36%; vertical-align: middle;">&#160;</td>
            <td style="width: 27.64%; vertical-align: middle;">
              <div style="text-align: center; color: #000000;">August 24, 2022</div>
            </td>
          </tr>
          <tr>
            <td style="width: 28%; vertical-align: middle; border-top: #000000 2px solid;">
              <div style="color: #000000;">Otis W. Brawley</div>
            </td>
            <td style="width: 2%; vertical-align: middle;">&#160;</td>
            <td style="width: 40%; vertical-align: middle;">&#160;</td>
            <td style="width: 2.36%; vertical-align: middle;">&#160;</td>
            <td style="width: 27.64%; vertical-align: middle;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 28%; vertical-align: middle;">&#160;</td>
            <td style="width: 2%; vertical-align: middle;">&#160;</td>
            <td style="width: 40%; vertical-align: bottom;">&#160;</td>
            <td style="width: 2.36%; vertical-align: middle;">&#160;</td>
            <td style="width: 27.64%; vertical-align: bottom;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 28%; vertical-align: middle; border-bottom: #000000 2px solid;">
              <div style="color: #000000;">/s/ Gregory Freitag</div>
            </td>
            <td style="width: 2%; vertical-align: middle;">&#160;</td>
            <td style="width: 40%; vertical-align: bottom;">
              <div style="text-align: center; color: #000000;">Director</div>
            </td>
            <td style="width: 2.36%; vertical-align: middle;">&#160;</td>
            <td style="width: 27.64%; vertical-align: bottom;">
              <div style="text-align: center; color: #000000;">August 24, 2022</div>
            </td>
          </tr>
          <tr>
            <td style="width: 28%; vertical-align: middle; border-top: #000000 2px solid;">
              <div style="color: #000000;">Gregory Freitag</div>
              <div><br>
              </div>
            </td>
            <td style="width: 2%; vertical-align: middle;">&#160;</td>
            <td style="width: 40%; vertical-align: middle;">&#160;</td>
            <td style="width: 2.36%; vertical-align: middle;">&#160;</td>
            <td style="width: 27.64%; vertical-align: middle;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 28%; vertical-align: middle; border-bottom: #000000 2px solid;">
              <div style="color: #000000;">/s/ Ilian Iliev</div>
            </td>
            <td style="width: 2%; vertical-align: middle;">&#160;</td>
            <td style="width: 40%; vertical-align: bottom;">
              <div style="text-align: center; color: #000000;">Director</div>
            </td>
            <td style="width: 2.36%; vertical-align: middle;">&#160;</td>
            <td style="width: 27.64%; vertical-align: bottom;">
              <div style="text-align: center; color: #000000;">August 24, 2022</div>
            </td>
          </tr>
          <tr>
            <td style="width: 28%; vertical-align: middle; border-top: #000000 2px solid;">
              <div style="color: #000000;">Ilian Iliev</div>
              <div><br>
              </div>
            </td>
            <td style="width: 2%; vertical-align: middle;">&#160;</td>
            <td style="width: 40%; vertical-align: middle;">&#160;</td>
            <td style="width: 2.36%; vertical-align: middle;">&#160;</td>
            <td style="width: 27.64%; vertical-align: middle;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 28%; vertical-align: middle; border-bottom: #000000 2px solid;">
              <div style="color: #000000;">/s/ Richard Sykes</div>
            </td>
            <td style="width: 2%; vertical-align: middle;">&#160;</td>
            <td style="width: 40%; vertical-align: bottom;">
              <div style="text-align: center; color: #000000;">Director</div>
            </td>
            <td style="width: 2.36%; vertical-align: middle;">&#160;</td>
            <td style="width: 27.64%; vertical-align: bottom;">
              <div style="text-align: center; color: #000000;">August 24, 2022</div>
            </td>
          </tr>
          <tr>
            <td style="width: 28%; vertical-align: middle; border-top: #000000 2px solid;">
              <div style="color: #000000;">Sir Richard Sykes</div>
            </td>
            <td style="width: 2%; vertical-align: middle;">&#160;</td>
            <td style="width: 40%; vertical-align: middle;">&#160;</td>
            <td style="width: 2.36%; vertical-align: middle;">&#160;</td>
            <td style="width: 27.64%; vertical-align: middle;">&#160;</td>
          </tr>

      </table>
      <div><br>
      </div>
      <br>
      <div>
        <div>
          <hr style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;" align="center" noshade="noshade"></div>
      </div>
    </div>
  </div>
</body>
</html>
[{"type": "S-8", "sequence": "1", "filename": "ny20005031x3_s8.htm", "description": "S-8", "secsgml_size_bytes": 38741}]
{"company-data": {"conformed-name": "PDS Biotechnology Corp", "cik": "0001472091", "assigned-sic": "2834", "irs-number": "264231384", "state-of-incorporation": "DE", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "S-8", "act": "33", "file-number": "333-267042", "film-number": "221191596"}, "business-address": {"street1": "25B VREELAND ROAD", "street2": "SUITE 300", "city": "FLORHAM PARK", "state": "NJ", "zip": "07932", "phone": "800-208-3343"}, "mail-address": {"street1": "25B VREELAND ROAD", "street2": "SUITE 300", "city": "FLORHAM PARK", "state": "NJ", "zip": "07932"}, "former-company": {"former-conformed-name": "Edge Therapeutics, Inc.", "date-changed": "20090911"}}
As filed with the Securities and Exchange Commission on August 24, 2022
Registration No. 333-_________
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM S-8
REGISTRATION STATEMENT
UNDER
THE SECURITIES ACT OF 1933
PDS Biotechnology Corporation
(Exact name of registrant as specified in its charter)
Delaware
26-4231384
(State or other jurisdiction of incorporation or organization)
(I.R.S. Employer Identification No.)
25B Vreeland Road, Suite 300
Florham Park, NJ
07932
(Address of Principal Executive Offices)
(Zip Code)
PDS Biotechnology Corporation 2019 Inducement Plan, as amended
(Full title of the plans)
Frank Bedu-Addo
President and Chief Executive Officer
PDS Biotechnology Corporation
25B Vreeland Road, Suite 300
Florham Park, NJ 07932
(800) 208-3343
(Name, address and telephone number, including area code, of agent for service)
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of "large accelerated filer," "accelerated
        filer" and "smaller reporting company" in Rule 12b-2 of the Exchange Act.
Large Accelerated filer
☐
Accelerated filer
☐
Non-accelerated filer
☒
Smaller reporting company
☒
Emerging growth company
☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to
        Section 7(a)(2)(B) of the Securities Act.
☐
Part II
Information Required In The Registration Statement
This Registration Statement relates to the registration of an additional 600,000 shares (the "
Shares
") of the Registrant's Common Stock. The Shares are securities of the same class and relate to the same employee benefit plan, the PDS Biotechnology Corporation 2019 Inducement Plan, which
            was amended effective as of May 17, 2022 (in the form attached hereto as Exhibit 99.1) (the "
Inducement Plan
"), as those registered
            pursuant to the Registrant's registration statements on Form S-8, previously filed with the Securities and Exchange Commission on
November 14, 2019
            (Registration No. 333-234693)
and
November 15, 2021 (Registration No. 333-261072)
.
In accordance with General Instruction E of Form S-8, the contents of the Registrant's registration statements on Form S-8 filed with the Securities and Exchange
            Commission on
November 14, 2019 (Registration No. 333-234693)
and
November 15, 2021 (Registration No. 333-261072)
are incorporated herein by reference (solely to the extent the
            contents of such registration statement relate to the Inducement Plan) and the information required by Part II is omitted, except as supplemented by the information set forth below.
Item 8.
Exhibits.
Exhibit No.
Description
4.1
Eighth Amended and Restated Certificate of Incorporation of the Registrant (incorporated by reference to Exhibit 3.1 to the Current Report on Form 8-K filed with the Commission on October 6, 2015).
4.2
Certificate of Amendment of the Eighth Amended and Restated Certificate of Incorporation of the Registrant (incorporated by reference to Exhibit 3.1 to the Current Report on Form 8-K filed with the Commission on
                March 18, 2019).
4.3
Certificate of Amendment of the Eighth Amended and Restated Certificate of Incorporation of the Registrant (incorporated by reference to Exhibit 3.2 to the Current Report on Form 8-K filed with the Commission on
                March 18, 2019).
4.4
Third Amended and Restated Bylaws of the Registrant (incorporated by reference to Exhibit 3.1 to the Current Report on Form 8-K filed with the Commission on March 15, 2022).
4.5
Form of Certificate of Common Stock (incorporated by reference to Exhibit 4.1 to the Registrant's Pre-Effective Amendment No. 1 to the Registration Statement on Form S-1 (File No. 333- 206416) filed with the
                Commission on September 21, 2015).
5.1*
Opinion of DLA Piper LLP (US).
23.1*
Consent of KPMG LLP.
23.2*
Consent of DLA Piper LLP (US) (included in Exhibit 5.1).
24
Power of Attorney (contained on the signature page hereto).
99.1
PDS Biotechnology Corporation 2019 Inducement Plan, as amended (incorporated by reference to Exhibit 10.1 to the Current Report on Form 8-K filed with the Commission on May 18, 2022).
107*
Filing Fee Table
*
Filed herewith
SIGNATURE
Pursuant to the requirements of the Securities Act of 1933, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on
        Form S-8 and has duly caused this Registration Statement with respect to the PDS Biotechnology Corporation 2019 Inducement Plan, as amended, to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Florham Park,
        State of New Jersey, on August 24, 2022.
PDS Biotechnology Corporation
By:
/s/ Frank Bedu-Addo
Name:
Frank Bedu-Addo
Title:
President and Chief Executive Officer
POWER OF ATTORNEY
The officers and directors of PDS Biotechnology Corporation whose signatures appear below hereby constitute and appoint Frank Bedu-Addo and Matthew Hill, and each of them, their
        true and lawful attorneys and agents, with full power of substitution, each with power to act alone, to sign and execute on behalf of the undersigned this Registration Statement on Form S-8 with respect to the PDS Biotechnology Corporation 2019
        Inducement Plan, as amended, and any amendment or amendments thereto, and each of the undersigned does hereby ratify and confirm all that each attorney and agent, or his or her substitutes, shall do or cause to be done by virtue hereof.
Pursuant to the requirements of the Securities Act of 1933, this Registration Statement has been signed by the following persons in the capacities and on the date indicated.
Signature
Title
Date
/s/ Frank Bedu-Addo
President, Chief Executive Officer and Director
August 24, 2022
Frank Bedu-Addo
(Principal Executive Officer)
/s/ Matthew Hill
Chief Financial Officer
August 24, 2022
Matthew Hill
(Principal Financial and Accounting Officer)
/s/ Stephen Glover
Director
August 24, 2022
Stephen Glover
/s/ Kamil Ali-Jackson
Director
August 24, 2022
Kamil Ali-Jackson
/s/ Otis W. Brawley
Director
August 24, 2022
Otis W. Brawley
/s/ Gregory Freitag
Director
August 24, 2022
Gregory Freitag
/s/ Ilian Iliev
Director
August 24, 2022
Ilian Iliev
/s/ Richard Sykes
Director
August 24, 2022
Sir Richard Sykes